[HTML][HTML] Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
G Agnelli, P Prandoni, MG Santamaria… - … England Journal of …, 2001 - Mass Medical Soc
Background In patients with idiopathic deep venous thrombosis, continuing anticoagulant
therapy beyond three months is associated with a reduced incidence of recurrent thrombosis …
therapy beyond three months is associated with a reduced incidence of recurrent thrombosis …
[HTML][HTML] Systemic lupus erythematosus and thrombosis
M Bazzan, A Vaccarino, F Marletto - Thrombosis journal, 2015 - Springer
Abstract Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune
disease. Clinical presentation is extremely variable and heterogeneous. It has been shown …
disease. Clinical presentation is extremely variable and heterogeneous. It has been shown …
[PDF][PDF] Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in …
M Verso, G Agnelli, S Bertoglio… - Journal of Clinical …, 2005 - researchgate.net
Purpose The extent of venous thromboembolism (VTE) associated with central vein
catheters (CVC) in cancer patients remains unclear. The aim of this study was to evaluate …
catheters (CVC) in cancer patients remains unclear. The aim of this study was to evaluate …
Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients
M Bazzan, B Montaruli, S Sciascia, D Cosseddu… - Internal and Emergency …, 2020 - Springer
Both arterial and venous thrombotic complications have been reported in patients affected
by COVID-19, especially in those critically ill. An emerging body of evidence is supporting …
by COVID-19, especially in those critically ill. An emerging body of evidence is supporting …
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients
Deep vein thrombosis of upper limb is a common complication of CVC in patients with
cancer. In these patients the risk factors for CVC-related thrombosis are not completely …
cancer. In these patients the risk factors for CVC-related thrombosis are not completely …
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism
R Pesavento, L Filippi, A Palla, A Visonà… - European …, 2017 - Eur Respiratory Soc
The impact of residual pulmonary obstruction on the outcome of patients with pulmonary
embolism is uncertain. We recruited 647 consecutive symptomatic patients with a first …
embolism is uncertain. We recruited 647 consecutive symptomatic patients with a first …
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients
S Sciascia, M Radin, I Cecchi, ML Bertolaccini… - …, 2021 - academic.oup.com
Objectives To identify the aggregation of patients with aPL into different subgroups sharing
common features in terms of clinical and laboratory phenotypes. Methods We applied a …
common features in terms of clinical and laboratory phenotypes. Methods We applied a …
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome
S Sciascia, M Radin, M Bazzan… - Internal and emergency …, 2017 - Springer
The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by
vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for …
vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for …
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic …
E Crisà, E Venturino, R Passera, M Prina… - Annals of …, 2010 - Springer
The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still
undetermined. In particular, the recommended target of hematocrit (Hct)< 0.45 has been …
undetermined. In particular, the recommended target of hematocrit (Hct)< 0.45 has been …
Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)
E Rota, M Bazzan, G Fantino - Thrombosis and haemostasis, 2008 - thieme-connect.com
Heparin-induced thrombocytopenia (HIT) is an immune-mediated, life-threatening adverse
effect of unfractionated heparin (UFH) or, less commonly, low-molecularweight heparin …
effect of unfractionated heparin (UFH) or, less commonly, low-molecularweight heparin …